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Abstract
In estrogen receptor-positive (ER+) breast cancer, it is recognized that metastases may 
develop after a long period of dormancy. Bone marrow (BM) vascular niche is where 
the dormant tumor cells are most likely to reside. So far, it is not fully understood 
why the dormant tumor cells become proliferative and eventually generate tumor. 
We hypothesized that therapeutic or menopause-related estrogen depletion may be 
the switch behind dormant ER+ tumor cell awakening in BM. We utilized an existing 
experimental model of BM endothelial niche that can simulate ER+ tumor cell dormancy 
to test our hypothesis. In results, estrogen depletion paradoxically promoted ER+ tumor 
cell proliferation in the BM endothelial niche, and their molecular phenotype shifted 
from dormant to awaken. Following estrogen depletion, the BM niche cells produced 
angiopoietin-2 (ANGPT2), which destabilized niche endothelium by interfering  
ANGPT1/Tie2 signaling, and promoted ER+ tumor cell survival under estrogen deficiency 
via cell surface integrin β1. Knockdown of ANGPT2 completely negated ER+ tumor cell 
awakening in the niche. Furthermore, ANGPT2 expression in ER+ tumor human samples 
was associated with increased risk of distant metastasis only in those who underwent 
adjuvant estrogen depletion therapy, not in those who did not undergo adjuvant 
therapy. In conclusion, we demonstrate that ANGPT2 signaling activated after estrogen 
depletion paradoxically triggers ER+ tumor cell awakening from dormancy in their BM 
niche, partly indirectly via endothelial Tie2 receptor and partly directly via tumor cell 
surface integrin β1.
Introduction
Tumor cells frequently escape the primary site and 
disseminate into multiple distant organs such as bone 
marrow (BM) (Aguirre-Ghiso 2007). The cells may 
remain there in a dormant, growth-arrested state for 
a long time. Disseminated dormant tumor cells can 
threaten patients’ survival, since the tumor cells are 
resistant to standard adjuvant therapies, can evade 
current monitoring protocols (Braun et  al. 2000) and 
eventually be reactivated to form metastatic tumors 
(Janni et al. 2005, Janni et al. 2011). Recurrence after long 
period of dormancy is especially common in estrogen 
receptor-positive (ER+) breast cancer (Han et al. 2016, 
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Zhang et  al. 2013). While estrogen receptor-negative 
(ER−) cancer rarely recurs after 5 years, ER+ cancer 
often recurs even decades after otherwise successful 
primary tumor treatment. Understanding the molecular 
mechanisms of tumor dormancy and reactivation can 
facilitate the development of therapeutic strategies 
against metastatic recurrence (Giancotti 2013), 
comprising most of the ER+ breast cancer patient 
mortality (Goss & Chambers 2010).
Tumor cell dormancy seems to be regulated by a 
special environment, called a niche, which exists in 
lymph node, lung or BM (Aguirre-Ghiso 2007). Since 
niche exists only sparsely and dormant tumor cells 
are even sparser, human or animal study of tumor 
cell dormancy in niche is a technical challenge itself. 
In  vitro models of tumor dormancy, therefore, have 
crucial importance in this field (Barkan & Green 
2011). For instance, the BM niche contains many 
types of stromal cells, including mesenchymal stem 
cells (MSCs), osteoblasts, pericytes, fibroblasts and 
endothelial cells (ECs) (Mendez-Ferrer et  al. 2010, 
Kunisaki et al. 2013). Among the cellular components, 
the role of EC is an emerging topic of importance 
(Ghajar 2015). Ghajar and coworkers (2013) found out 
that endothelial components regulate breast tumor 
cell dormancy in lung and BM perivascular niches by 
utilizing both in  vitro co-culture models of BM niche 
and in vivo models. Similarly, Marlow and coworkers 
(2013) developed a three-dimensional co-culture 
model of BM niche by mixing MSCs, osteoblasts and 
ECs, which successfully reproduced dormancy of bone 
metastatic breast cancer in human.
In general, ER+ tumor cells need estrogen for survival 
and proliferation. However, many metastatic events of ER+ 
breast cancer come after years of adjuvant antiestrogen 
therapy or after menopause when systemic estrogen levels 
become extremely low (Zhang et al. 2013). Furthermore, 
it is argued that estrogen depletion may promote, 
paradoxically, breast cancer metastasis. For example, 
Ottewell and coworkers (2014) reported that ER- breast 
cancer bone metastasis in animal model did not decrease 
but increased after ovariectomy, especially via osteoclast 
activation. Similarly, McBryan and coworkers (2015) 
reported that antiestrogen treatment using tamoxifen 
promoted particularly metastatic recurrence of endocrine-
resistant ER+ breast cancer. Both results imply that 
estrogen deficiency can remodel the microenvironment 
of secondary organs, which may also support survival and 
metastasis of endocrine-sensitive ER+ tumor cells.
Angiopoietin-2 (ANGPT2) may be the switch 
underling ER+ breast cancer relapse after estrogen 
depletion. ANGPT2 is expressed by endothelium and 
acts as an autocrine or paracrine antagonist of ANGPT1 
(Augustin et  al. 2009). It has been gaining attention 
as a promising target in cancer therapy, and specific 
inhibitors are now available (Saharinen et  al. 2011, 
Eroglu et al. 2013). In primary organ, ANGPT2 directly 
stimulates tumor angiogenesis (Eroglu et  al. 2013). 
In metastatic sites, ANGPT2 loosens the endothelial 
cell–cell junction, which enhances extravasation of 
disseminated tumor cells (Schulz et al. 2011, Holopainen 
et al. 2012, Avraham et al. 2014). Yet, its role after tumor 
cell extravasation, especially on tumor cell dormancy and 
reawakening, has not yet been explored. Since estrogen 
regulates ANGPT1, 2 expressions in other tissues (Ardelt 
et al. 2005, Matsuoka-Sakata et al. 2006, Bonagura et al. 
2010, Harfouche et  al. 2011), we hypothesized that 
estrogen deficiency may modulate ANGPT2 signaling 
in the BM niche, triggering ER+ tumor cell awakening 
from dormancy. Herein, we demonstrate that estrogen-
deficient BM niche overexpresses angiopoietin-2, which 
negates ER+ tumor cell dormancy and eventually 
promotes estrogen-independent tumor growth.
Materials and methods
Cell lines and culture conditions
Breast cancer cell lines MCF7, BT474, MDA-MB-361 and 
MDA-MB-231 were obtained from the American Tissue 
Culture Collection (ATCC) and grown in complete 
RPMI-1640 medium (Gibco) supplemented with 10% 
fetal bovine serum (FBS; Gibco), 100 unit/mL penicillin 
and 100 μg/mL streptomycin (passage number ranged 
from 9 to 15). Above cell lines were authenticated 
by standard short tandem repeat (STR) DNA typing 
methodology before being purchased from the ATCC. 
Primary human umbilical vein endothelial cells (ECs) at 
second passage were obtained commercially (C-12203, 
lot #3070401, PromoCell GmbH, Heidelberg, Germany) 
and grown in endothelial cell growth medium 2 (EGM2; 
PromoCell, Heidelberg, Germany) in a humidified 
chamber (37°C, 5% CO2). Primary human bone marrow 
mesenchymal stem cells (BM MSCs) at second passage 
were obtained from Yonsei Cell Therapy Center (lot 
#B090429-04; #B110124-07, Seoul, Korea). BM MSCs were 
maintained in low glucose Dulbecco’s Modified Eagle 
Medium (DMEM; Gibco) supplemented with 10% FBS, 
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100 unit/mL penicillin and 100 μg/mL streptomycin. 
Endothelial cells (ECs) and BM MSCs isolated between 
passages 5 and 10 were used in these experiments.
Generation of tumor cells expressing fluorescent tags
Tumor cell lines were tagged with red fluorescent protein 
(RFP) or enhanced green fluorescent protein (GFP) using 
a lentiviral transduction system. Briefly, pLenti CMV/TO 
Puro empty vector was obtained from Addgene (Addgene 
plasmid 17482; Cambridge, MA, USA) 49. RFP and 
GFP (sequences obtained from GenBank) were cloned 
into pLenti CMV/TO Puro empty vector. Lentivirus 
was generated by co-transfection of packaging vectors 
pMDLg/pRRE, pMD2G, pRSV-Rev (Addgene plasmids 
12251, 12253, and 12259) and pLenti CMV/TO Puro-RFP 
or pLenti CMV/TO Puro-GFP into 293T cells with 2.5 M 
calcium chloride. RFP- or GFP-expressing tumor cells lines 
were generated by lentiviral infection and selection for 
1 week in 1 μg/mL puromycin.
In vitro model of bone marrow niche
MSCs and ECs were co-cultured in EGM2 for 5–7 days 
to reach confluence. For three-dimensional (3D) culture, 
growth-factor-reduced, phenol-red-free Matrigel matrix 
(Corning) was used to coat the vessels before cell seeding. 
To discriminate ECs from MSCs, ECs were stained 
with carboxyfluorescein succinimidyl ester (CFSE, Life 
Technologies) before co-culture. Cell numbers and 
culture volumes were as follows: 5 × 103 MSCs, 2 × 103 
ECs in microfluidic plates. 5 × 104 MSCs, 2 × 104 ECs and 
200 μL EGM2 per well in 96-well microplates; 2 × 105 
MSCs, 5 × 104 ECs and 2 mL EGM2 per well in 6-well 
microplates; and 2 × 106 MSCs, 5 × 105 ECs and 10 mL 
EGM2 in 100 mm dishes.
Monitoring tumor cell proliferation using continuous 
fluidic cell culture system
A microfluidic live-cell imaging platform (CellASIC 
ONIX Microfluidic Platform, EMD Millipore) was 
utilized to supply nutrients and oxygen and remove 
wastes with minimal stress to cells. Cell culture was 
performed according to the manufacturer’s instructions. 
Briefly, 10 μL MSC and EC cell suspensions (1 × 106 total 
cells/mL) was loaded onto a microfluidic culture plate 
(M04S, EMD Millipore), which has a compatible culture 
volume as that of 384-well microplate. The plate 
was attached to the platform controlling perfusion 
flow, temperature and gas composition. An inverted 
fluorescence microscope was used for live-cell imaging 
with the 40× objective. The cells were incubated (EGM2, 
37°C, 5% CO2) for 5–7 days until reaching confluence. 
Then, fluorescence-expressing tumor cells were seeded 
sparsely onto BM niche culture plates. Tumor cell 
seeding numbers were as follows: 0.5 × 102 cells per well 
in microfluidic plate, 2 × 102 cells per well in 96-well 
microplates, 4 × 103 cells per well in 6-well microplates 
and 2 × 104 MCF7 in 100 mm dishes. For microfluidic 
culture, tumor cell proliferation was monitored 
by capturing time-lapse images of the cells using a 
fluorescence microscope (Nikon Eclipse Ti, Nikon 
Instruments). For conventional culture, a fluorescence 
microplate reader (Varioskan Flash Multimode Reader, 
Thermo Scientific) was used to measure cell fluorescence 
every 24 h after cell seeding. Fluorescence intensity was 
measured using bottom optic readings. Excitation/
emission wavelengths were 553/574 nm for RFP and 
488/507 nm for GFP.
To compare proliferative capacities of tumor cells 
co-cultured with different stromal cell compositions 
(MSCs, MSCs-ECs or no stromal cells as a control), all 
cells were harvested by trypsinization after co-culturing 
for up to 7 days. Fluorescence-positive cells were sorted 
and collected using fluorescence-activated cell sorting 
(FACS) (FACSAria cell sorter; BD Bioscience, San Jose, CA, 
USA), and seeded onto new empty plates (2 × 103 cells per 
well in 96-well microplates). Cell proliferative capacity 
was assessed again by measuring fluorescence intensity 
every 24 h.
Flow cytometry to detect ERK1/2 and p38 activities
GFP-expressing tumor cells were cultured alone or with 
MSCs and/or ECs in 100 mm dishes for 7 days. Cells were 
trypsinized, washed with phosphate-buffered saline 
(PBS) and fixed with 4% paraformaldehyde for 10 min. 
The fixed cells were chilled on ice and permeabilized 
with 90% methanol for 30 min. Then, 1 × 106 cells per 
experimental condition were aliquoted, washed and 
resuspended in 100 μL fluorochrome-conjugated primary 
antibodies against p38, phosphorylated p38 (Santa Cruz 
Biotechnology), ERK1/2 and phosphorylated ERK1/2 
(Cell Signaling Technology) at the manufacturer’s 
recommended concentrations, and incubated for 1 h. 
For isotype control, fluorochrome-conjugated rabbit IgG 
was used at the same concentration. Cells were washed, 
resuspended in PBS, sorted for GFP fluorescence and 
analyzed using the FACSAria cell sorter.
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Estrogen depletion and supplement in culture
FBS stripped with charcoal-dextran was purchased 
from Gemini Bio-Products (Gemini Bio-Products, 
West Sacramento, CA, USA). To evaluate the effect of 
estrogen depletion on BM niche, MSCs and/or ECs 
were cultured in phenol-red-free RPMI 1640 containing 
10% charcoal-stripped FBS supplemented with or 
without 200 pg/mL 17β-estradiol (E2758, Sigma-Aldrich). 
Because the charcoal-stripping process eliminates 
estrogen and other steroidal hormones essential for 
primary EC survival, hydrocortisone (0.2 μg/mL) was 
added to the final medium. To supplement estrogen, 
17-β estradiol (Sigma-Aldrich) was added.
Modulation of receptor–ligand interaction
To evaluate the effect of angiopietin-1, 2 on tumor cell 
proliferation, cultures were treated with 0, 50, 100 or 
500 ng/mL recombinant human angiopoietin-1 and 
recombinant human angiopoeitin-2 (R&D Systems). 
To block angiopoietin-1 and Tie2 receptor interaction, 
cultures were treated with 10 μg/mL of human Tie2 
affinity-purified polyclonal antibody (R&D Systems). To 
knockdown angiopoietin-2 in culture, short-inhibiting 
RNAs (siRNAs) were used. Three different siRNAs that 
are known to block specifically angiopoietin-2 mRNA 
were generated:
#1  5′-GGAAGAGCAUGGACAGCAUAGGA-3′ (D’Souza 
et al. 2012)
#2  5′-AGAACCAGACGGCUGUGAUGAUAGAAA-3′ 
(Daly et al. 2006)
#3  5′-CCAGACGGCUGUGAUGAUA-3′ (Mangan et al. 
2007)
Negative and positive control siRNAs were obtained 
from GenePharma (Suzhou, China). Cells were 
prepared and cultured as described above and siRNAs 
were transfected using transfection reagent G-Fectin 
(Genolution Pharmaceuticals. Seoul, Korea) according 
to the manufacturer’s protocol. Briefly, 1 μL G-Fectin 
and 5 pmol siRNA were incubated in 50 μL PBS at room 
temperature for 10 min, and added to cell culture plate 
(24-well). Culture medium was replaced 8 h after 
transfection to minimize cytotoxicity. Angiopoietin-2 
knockdown was assessed by PCR using total RNA extracted 
from cells 48 h post-transfection.
To knockdown ITGB1, we used the SureSilencing 
shRNA plasmid for human ITGB1 (KH00650G for 
the GFP) and a scrambled sequence negative control 
plasmid (SABiosciences, Frederick, VA, USA), as described 
previously (Choi et al. 2012). The shRNA target sequence 
for ITGB1 was as follows: 5′-TGT GCT CAG TCT TAC TAA 
TAA-3′. The cells were seeded and transfected using the 
Attractene Transfection Reagent (Qiagen) according to the 
manufacturer’s protocol.
RNA extraction and reverse transcription polymerase 
chain reaction (RT-PCR)
As described previously (Kang et  al. 2013), total RNA 
was isolated from cells using an RNeasy Protect Mini Kit 
(Qiagen) according to the manufacturer’s protocol. The 
Super-Script III Reverse Transcriptase kit (Invitrogen) was 
used to synthesize cDNA. Polymerase chain reactions 
(PCRs) were performed with HotStarTaq DNA polymerase 
(Qiagen) and the following conditions: denaturation at 
95°C for 15 min, and 28 cycles of 95°C for 40 s, 52°C for 
1 min and 72°C for 1 min, with a final extension for 10 min 
at 72°C. Expression levels of GAPDH were assessed as an 
internal control in all reactions. The following primers 
were used for PCR: forward primer for angiopoietin-1 
5′-GAAGGGAACCGAGCCTATTC-3′, reverse primer 
5′-GGGCACATTTGCACATACAG-3′; forward primer 
for angiopoietin-2 5′-TGGGATTTGGTAACCCTTCA-3′, 
reverse primer 5′-GGTTGGCTGATGCTGCTTAT-3′.
Western blotting assay
As described previously (Kang et  al. 2013), cells were 
trypsinized and lysed by Pro-Prep protein extraction 
kit (iNtRON Biotechnology, Seongnam, Korea). Equal 
amounts of protein extracts (20 μg) were separated 
by sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis and transferred to a nitrocellulose membrane 
(Invitrogen). Blots were blocked with 5% nonfat dry 
milk at room temperature. The blots were incubated with 
antibodies specific for angiopoietin-1 (ab183701, Abcam), 
angiopoietin-2 (ab155106, Abcam), phosphorylated 
Tie2 (Tyr992, #4221, Cell Signaling Technology), Tie2 
(sc-9026), thrombospondin-1 (sc-59886) and β-actin 
(Santa Cruz Biotechnology) at specific dilution, followed 
by incubation with peroxidase-labeled secondary 
antibodies. Immunoreactive proteins were visualized 
using an enhanced chemiluminescence detection kit 
(Santa Cruz Biotechnology). Blot images were captured 
using ImageQuant LAS 4000 biomolecular imager 
(GE  Healthcare Life Sciences). Blot intensities were 
quantified using ImageJ 1.48v software (http://imagej.
nih.gov/ij) (Schneider et al. 2012).
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Graphics and statistical analysis
For survival analysis of human patients, statistical 
significance was determined using Kaplan–Meier method 
and log-rank test. For in vitro experiments, statistical 
significance was determined using Student’s t-test and 
ANOVA. Results were considered to be significant at 
P < 0.05. Statistical analyses were computed with IBM SPSS 
Statistics 20 software. All graphical presentations were 
created using GraphPad Prism 6 software.
Results
Angiopoietin-1, 2 regulate ER+ tumor cell dormancy in 
BM endothelial niche
Angiopoietin-1/Tie2 signaling is active in the BM 
niche, mainly participating in hematopoietic stem cell 
quiescence (Arai et  al. 2004). If angiopoietin signaling 
does have a role in ER+ tumor metastatic recurrence, 
it is probably working also in the BM niche where 
disseminated tumor cells are most likely to reside. To 
test the impact of angiopoietin signaling on ER+ breast 
tumor dormancy in BM niche, we utilized existing in vitro 
models (Barkan & Green 2011, Ghajar et al. 2013, Marlow 
et al. 2013). Briefly, to create a microenvironment similar 
to BM niche, human BM-derived MSCs and/or ECs were 
co-seeded onto extracellular matrix-coated microplates 
(Fig. 1A). These were designated as ‘mesenchymal niche’ 
or ‘endothelial niche’, based on the presence of ECs. 
Without ECs, BM-derived stromal cells (mesenchymal 
niche) generally support breast tumor cell growth, whereas 
EC-contained niche (endothelial niche) inhibits tumor 
cell growth (Marlow et al. 2013). To optimize the system 
for our studies, a few modifications have been introduced: 
a commercial continuous fluidic cell culture system was 
used to supply nutrients and oxygen and remove wastes 
with minimal stress to cells during long-term culture; 
charcoal-stripping fetal bovine serum (FBS) was used to 
eliminate serum-derived estrogen.
The niches were incubated until their cells reaching 
confluence in medium containing 10% charcoal-stripped 
FBS supplemented with estradiol (E2) 200 pg/mL. Then, 
fluorescence-expressing ER+ human breast tumor cells 
were seeded sparsely onto the niche surface. Stromal 
cells and tumor cell seeding densities were determined 
by references and our own preliminary studies 
(Supplementary Fig. 1, see section on supplementary data 
given at the end of this article). Tumor cell proliferation 
was monitored by its fluorescence visualization using 
a microplate reader and a microscope. MCF7 breast 
tumor cells exhibited significant growth suppressions 
in endothelial niche compared with those of the 
mesenchymal niche or cultured alone (Fig.  1B and C). 
The results were repeated in other ER+ tumor cell lines 
BT474 and MDA-MB-361 (Supplementary Fig. 2A and B). 
An ER-negative cell line MDA-MB-231 did not show 
growth suppression in endothelial niche (compared 
with those cultured alone), but its proliferation rate in 
mesenchymal niche was significantly higher than those 
in endothelial niche or cultured alone (Supplementary 
Fig. 2C). Mitogen-activated protein (MAP) kinases activity 
ratio of ERK1/2 and p38 (ERK/p38 ratio) can be used as 
an indicator of tumor cell dormancy and awakening: 
proliferative tumor cells exhibit high ERK/p38 ratio, while 
dormant tumor cells exhibit low ERK/p38 ratio (Sosa et al. 
2011). Since both proteins are active in phosphorylated 
forms, we analyzed their phosphorylation status in MCF7 
cells grown in mesenchymal niche and endothelial 
niche by FACS. Compared with those cultured alone or 
in mesenchymal niche, tumor cells in endothelial niche 
exhibited a shift toward low ERK/p38 ratio (Fig.  1D). 
When the tumor cells cultured in endothelial niche were 
harvested and reseeded in empty plates, they started 
replication and generated tumor, implying that their 
tumorigenic potentials were maintained (Fig. 1E). Growth 
suppression of tumor cells in our endothelial niche model 
could be extended up to 3 weeks (Fig. 1F).
Vascular phenotype inside tumor can be switched 
by modulating angiopoeitin-1/Tie2 signaling (Reiss 
et  al. 2009). We tested the effect of angiopoietin-1/Tie2 
signaling modulation on tumor cell dormancy in BM 
endothelial niche. We added human Tie2-receptor-
specific blocking antibody (10 μg/mL) to culture medium 
of endothelial niche. Compared with untreated control, 
the growth of ER+ tumor cells in endothelial niche 
significantly increased upon Tie2 blockade (Fig.  2A). In 
contrast, recombinant human angiopoietin-1 (RhAng1) 
500 ng/mL treatment further suppressed tumor cell 
proliferation in endothelial niche (Fig.  2A). Again, Tie2 
blockade significantly increased tumor cell proliferation 
in RhAng1-treated endothelial niche. Meanwhile, the 
growth of tumor cells in mesenchymal niche or those 
cultured alone were not affected by either Tie2 blockade 
or RhAng1 (Fig. 2A). Tumor cell proliferation rates in the 
endothelial niches were correlated with their Tie2 receptor 
activities and thrombospondin-1 (TSP-1) levels (Fig. 2B). 
Next, tumor cell’s ERK/p38 activity ratio was examined. 
Upon Tie2 blockade, ERK/p38 high (awaken) MCF7 
cell population in endothelial niche increased while 
ERK/p38 low (dormant) population decreased (Fig.  3B). 
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Figure 1
ER+ breast tumor cell MCF7 dormancy in bone marrow endothelial niche models. (A) Experimental scheme. BM MSCs and/or ECs were seeded on 
96-well microplates and incubated until reaching confluence. For 3D cultures, Matrigel was coated (150 μL/cm2) onto the culture plate. Then, 
RFP-expressing tumor cells were sparsely seeded (200 cells/well) onto the niche cells or empty surfaces (control). Tumor cell proliferations were 
assessed by fluorescence intensity reader and microscope, and fluorescence-activated cell sorting (FACS). (B) Seven-day proliferation rates of MCF7 
cells in niches (five sample sets per group; error bars: ± standard deviation (s.d.) *P < 0.05). (C) Representative images of tumor cells in the niches, 
captured after 7 days of co-culture (left: fluorescence (red and green); right: bright-field. scale bar = 100 μm). For visualization, ECs were prestained 
with CFSE (green). (D) FACS analysis of ERK1/2 and p38 MAR kinase activities of MCF7 tumor cells in niche. Upper: tumor cell alone; middle: tumor 
cell in mesenchymal niche; lower: tumor cell in endothelial niche. Blank arrows: ERK/p38 ratio-low (dormant) population; filled arrows: ERK/p38 
ratio-high (awaken) population. (E) Replicative potentials of dormant MCF7 tumor cells. Tumor cells were harvested from niche and replated in 
96-well microplates (500 cells/well). Box-plots represent fluorescence intensity fold-changes for 7 days (five samples per condition. horizontal 
bar = mean). (F) Time-lapse images of tumor cell dormancy in niche. MCF7RFP cells were cultured in endothelial niche for up to 21 days (fresh 
medium replaced every 48 h). Cells remain at almost the same number during the period. (Upper: fluorescence (red); lower: bright-field. scale 
bar = 500 μm). BM MSC, bone marrow-derived mesenchymal stem cell; EC, endothelial cell; ER, estrogen receptor; MAP, Mitogen-activated protein; 
p-ERK1/2, phosphorylated ERK1/2; p-p38, phosphorylated p38; RFP, red fluorescence protein. A full colour version of this figure is available at 
http://dx.doi.org/10.1530/ERC-16-0086.
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In contrast, RhAng1 further increased dormant tumor cell 
population in endothelial niche (Fig.  2B). Combination 
of RhAng1 treatment and Tie2 blockade recovered the 
activity ratio of ERK/p38 MAP kinases in similar degree 
to those of untreated control (Fig. 2B). We also tested the 
effect of recombinant human angiopoietin-2 (RhAng2), 
a competitive antagonist of angiopoeitin-1. Similarly, 
RhAng2 500 ng/mL treatment promoted MCF7, BT474 
and MDA-MB-361 cell proliferations only in endothelial 
niche, not in mesenchymal niche or in empty plate 
(tumor cell alone) (Supplementary Fig. 3A, B and C).
Estrogen depletion negates ER+ tumor cell dormancy in 
BM endothelial niche via increased angiopoietin-2 
signaling
To test the effect of estrogen deficiency on ER+ breast tumor 
dormancy in BM niche, the growth rates and ERK/p38 
Figure 2
Disruption of endothelial angiopoietin-1/Tie2 signaling elicits awakening of dormant MCF7 tumor cells in endothelial niche. (A, B and C) To modulate 
endothelial angiopoietin-1/Tie2 signaling in culture, 500 ng/mL recombinant human angiopoietin-1 (RhAng1) or 10 μg/mL human Tie2 receptor-specific 
blocking antibody were treated on the niche models. ER+ tumor cell dormancy/awakening states in the niches were assessed by fluorescence intensity 
reader and FACS. (A) Relative tumor cell proliferation rates in niches. Cell proliferation rates for 3 days of RhAng1 and/or Tie2 blockade were analyzed. 
Data are presented as mean signaling intensity changes, relative to untreated control (n = 3 per condition. Error bar: ±s.d. *P < 0.05). (B) Endothelial niche 
Tie2 receptor phosphorylation and thrombospondin-1 (TSP-1) level changes upon Tie2 block, RhAng1, Tie2 block+RhAng1 or RhAng2 500 ng/mL. Above: 
representative lot images. Below: Blot quantification. Normalized to β-actin. Error bar: s.d. Cells were harvested after 1, 8 or 24 h of incubation. 
Experiments were done triplicated. (C) ERK1/2 and p38 MAR kinase activities of tumor cells in RhAng1 and/or Tie2 blocking antibody-treated niches. 
Filled arrows: ERK/p38 ratio-high population. Blank arrows: ERK/p38 ratio-low population. Black = untreated; red = Tie2 blocked; blue = RhAng1-treated; 
green = Tie2 blocked & RhAng1-treated endothelial niches. A full colour version of this figure is available at http://dx.doi.org/10.1530/ERC-16-0086.
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activity ratio of breast tumor cells in E2-supplemented 
and unsupplemented niches were compared (Fig.  3A). 
Three ER+ breast cancer cell lines (MCF7, BT474 and 
MDA-MB-361) and one ER- cell line (MDA-MB-231) 
were used. MCF7 represents luminal A (ER+, PR+, 
HER2-), which is totally dependent on estrogen to grow 
in culture. BT474 represents luminal B (mild ER+, PR+, 
strong HER2+), MDA-MB-361 also represents luminal B 
(ER+, PR+, strong HER2+), both of which are amenable to 
antiestrogen hormone therapy. MDA-MB-231 represents 
basal-like subtype (ER−, PR−, HER2−) and is independent 
of estrogen for growth. When cultured alone, ER+ tumor 
Figure 3
Increased ER+ tumor cell proliferation after estrogen depletion in bone marrow endothelial niche. (A) Experimental scheme. BM niche models were 
generated by co-culturing BM MSCs and/or ECs on ECM-coated microplates. GFP-expressing tumor cells were sparsely seeded (200 cells/well) onto the 
niche cells or empty surfaces (control). Tumor cell proliferations were compared in niches cultured using estrogen-supplemented (200 pg/mL) or 
un-supplemented (depleted) media. (B) Seven-day proliferation rates of tumor cells in niches. From left to right: ER+ MCF7, ER+ BT474, ER+ 
MDA-MB-361 and ER- MDA-MB-231. (Five sample sets per group; error bars: ±s.d. *P < 0.05). (C) FACS analysis of ERK1/2 and p38 MAR kinase activities  
of MCF7 tumor cells in estrogen-supplemented (blue) and estrogen-depleted (red) niches. Filled arrows: ERK/p38 ratio-high population. Blank arrows: 
ERK/p38 ratio-low population. A full colour version of this figure is available at http://dx.doi.org/10.1530/ERC-16-0086.
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cells grew significantly slower in absence of E2 than in 
presence of E2 (Fig. 3B), implying that estrogen promotes 
their growths. Similar growth trends were noted in 
mesenchymal niche too (Fig.  3B). In endothelial niche, 
contrastingly, ER+ tumor cells grew significantly faster 
in absence of E2 than in presence of E2 (Fig.  3B). Such 
reverse growth trends were not shown in experiments 
with ER- tumor cells (Fig.  3B). We also tested the effect 
of 4-hydroxytamoxifen (4-OHT), an active metabolite 
of tamoxifen (Mandlekar & Kong 2001), which can 
effectively suppress ER signaling and ER+ cell growth 
(Supplementary Fig.  4A and B). Treatment of 4-OHT 
stimulated MCF7, BT474 and MDA-MB-361 cell growth 
in endothelial niches, contrary to those cultured alone 
(Supplementary Fig. 4C and D).
We analyzed ERK/p38 activity ratio in ER+ 
MCF7 cells cultured alone, in mesenchymal niche or 
endothelial niche (Fig.  3C). Tumor cells cultured alone 
or in mesenchymal niche showed decreases in awaken 
population upon estrogen depletion (ERK/p38 activity 
ratio-high, 89.3 to 20.2% and 43.3 to 17.8%, respectively, 
Fig. 3C). Meanwhile, tumor cells cultured in endothelial 
niche exhibited increase in awaken subpopulation upon 
estrogen depletion (ERK/p38 activity ratio-high; 16.7 to 
33.6%, Fig.  3C), suggesting disruption of niche-induced 
tumor cell dormancy.
The results described above suggest that upon estrogen 
depletion, some tumor dormancy-related factors in 
endothelial niche changes. We focused on angiopoietin-1 
and 2 specifically. In ER+ breast tumor cells, estrogen 
downregulates angiopoeitin-1 mRNA in an ER-dependent 
manner (Harfouche et al. 2011). Such regulations may also 
be active in endothelial cells too. Since the paradoxical 
growth promoting effect of estrogen depletion was seen 
Figure 4
Effect of estrogen depletion on niche endothelial cell angiopoietin-1 and -2 expressions. (A abd B) BM MSC and EC cells were co-cultured with or 
without estradiol supplementation (200 pg/mL) for 3 days (RT-PCR) or 5 days (Western blotting). Cells were harvested and their expressions of 
angiopoietin-1, 2 mRNAs (ANGPT1, 2) and proteins (Ang1, 2) were compared by RT PCR (A) and Western blot (B). Specific knockdown of ANGPT2 was 
performed by transfecting siRNA ANGPT2 #1, #2, #3 in 6 h after tumor cell seeding. See ‘Materials and methods’ section for siRNA information. Data in 
graph (left) are presented as mean blot intensity relative to GAPDH (RT-PCR) or β-actin (Western blotting). Data in dot graph (right) are presented as 
Ang2 blot intensity relative to Ang1. All blots were quantified using ImageJ software (IJ 1.46r). (Three sample sets per group. Error bar: s.d. *P < 0.05.)
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only in endothelial niche, we analyzed the expressions 
of angiopoietin-1, 2 mRNAs and proteins in endothelial 
niche cells, in E2-supplemented and unsupplemented 
(depleted) conditions. In this experiment, tumor cells 
were not co-cultured. Angiopoietin-1 levels, as both 
mRNA and protein forms, were not significantly different 
in E2-supplemented and depleted endothelial niches 
(Fig.  4A and B). In contrast, angiopoietin-2 mRNA was 
expressed significantly higher in estrogen-depleted niche 
than in supplemented niche (Fig. 4A). Protein expression 
levels exhibited similar trends as well (Fig. 4B). To note, 
the relative ratio of angiopoietin-2 to angiopoetin-1 level 
also changed significantly (Fig. 4A and B).
Increased angiopoietin-2 in estrogen-depleted 
endothelial niche may have shifted tumor cell behavior 
from dormancy to awakening. This hypothesis was 
examined by specific knockdown of angiopoietin-2 on 
niches. Three short-inhibiting RNAs (siRNAs) binding 
to different angiopoietin-2 mRNA (ANGPT2) sequence 
(siRNA ANGPT2 #1, #2, #3) significantly attenuated its 
expressions in endothelial niche (Fig. 4A). Then, tumor 
cell proliferation rates upon ANGPT2 knockdown in 
niche were examined. After tumor cells seeded on to 
estrogen-deficient endothelial niche and mesenchymal 
niche, siRNAs were treated. After 72 h, all three ER+ 
tumor cells in estrogen-deficient endothelial niche 
did not proliferate when ANGPT2 was knocked down 
(Fig.  5A and B). In contrast, ANGPT2 knockdown had 
no significant effect on ER+ tumor cell proliferations in 
estrogen-deficient mesenchymal niche (Fig. 5A and B).
Angiopoietin-2 promotes ER+ tumor cell survival under 
estrogen depletion via integrin β1
As described above, RhAng2 treatment (500 ng/mL) 
increased ER+ tumor cell proliferations in otherwise 
growth-suppressing E2-supplemented endothelial 
niches (Supplementary Fig.  3A, B and C). RhAng2 had 
no effect on their proliferations in E2-supplemented 
mesenchymal niche (Supplementary Fig. 3A, B and C). 
However, in estrogen-depleted mesenchymal niches, 
RhAng2 increased tumor cell proliferations, although 
not always in significant degree and in dose-dependent 
manner (Supplementary Fig.  2). Since there is no 
Ang2-responsive ECs in mesenchymal niche, we 
hypothesized that angiopoietin-2 may act on tumor cells 
Figure 5
siRNA knockdown of ANGPT2 suppresses  
tumor cell proliferation in estrogen-deficient 
bone marrow endothelial niche. (A and B) 
GFP-expressing ER+ tumor cell lines were 
cultured in niches for 3 days with or without 
estradiol supplementation (200 ng/mL). Specific 
knockdown of ANGPT2 mRNA in niche was 
performed by transfecting siRNA #1, #2 or #3 in 
6 h after tumor cell seeding. (A) Relative tumor 
cell proliferation rates in niches. Cell 
proliferation rates for 3 days following siRNA 
transfection were analyzed using fluorescence 
intensity reader. Data are presented as mean 
signaling intensity change from day 0 to day 3 
relative to siRNA mock control (three sample 
sets per group; error bar: ±s.d. *P < 0.05, by 
Student’s t-test). (B) Representative images of 
mesenchymal niches and endothelial niches 
treated with siRNAs. Images were captured by 
fluorescence microscope after 3 days of 
co-culture (Upper: merged; left lower: 
bright-field; right lower: fluorescence (green). 
Scale bar = 50 μm). A full colour version of  
this figure is available at http://dx.doi.org/ 
10.1530/ERC-16-0086.
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directly. Interestingly, Imanishi and coworkers (2007, 
2011) reported that angiopoeitin-2 acts directly on ER+ 
tumor cells via ITGB1 and promoted their initial survival 
and metastatic growth at lung. Encouraged by the 
previous reports, we evaluated the effect of RhAng2 on 
ER+ tumor cell proliferation under estrogen deficiency. 
Tumor cells were cultured for 3 days in E2-supplemented 
or unsupplemented growth media containing varying 
concentrations of RhAng2 (0, 50, 100, 500 ng/mL, 
Fig.  6A). In presence of E2, RhAng2 had no effect on 
ER+ and ER- tumor cell proliferations (Fig.  6B). In 
absence of E2, however, RhAng2 promoted ER+ tumor 
cell proliferations in dose-dependent manner (Fig. 6C). 
ER- tumor cell proliferation was not affected by RhAng2 
(Fig.  6C). To find-out whether this was dependent on 
tumor cell ITGB1, we performed ITGB1 knockdown 
using shRNAs (Supplementary Fig. 6). ITGB1 knockdown 
itself had no effect on tumor cell growth under estrogen 
deficiency (Supplementary Fig. 6D). In contrast, ITGB1 
knockdown completely negated RhAng2’s proliferative 
effect under estrogen depletion (Fig. 6E).
Angiopoietin-1, 2 expressions correlate with ER+ breast 
cancer metastatic recurrences following antiestrogen 
endocrine therapy
Angiopoietin-2 overexpression in breast cancer is known 
to correlate with poor patient survival (Sfiligoi et al. 2003). 
According to our experimental data, its expression would 
be particularly associated with metastatic recurrence 
of ER+ subtype after adjuvant antiestrogen therapy. 
To test the hypothesis, we used a published dataset 
and a web-based program ‘KM plotter’ (http://kmplot.
com) that contain both gene expression and human 
Figure 6
Exogenous angiopoietin-2 promotes ER+ tumor cell survival under estrogen deficiency via cell surface integrin β1. (A) Experimental scheme. ER+ breast 
tumor cell lines MCF7, BT474, MDA-MB-361 and ER- cell line MDA-MB-231 were cultured in 96-well microplates using estradiol-supplemented (200 pg/mL) 
or un-supplemented (depleted) media. Recombinant human angiopoietin-2 (RhAng2, 0 ng/mL, 50 ng/mL, 100 ng/mL, 500 ng/mL) were treated 1 h  
after tumor cell seeding. After 48 h, tumor cell proliferation/viability of each condition was assessed using cell counting kit-8 (Dojindo Molecular 
Technologies, Rockville, MD, USA). (B, C and D) Tumor cell proliferation/viability in presence of RhAng2. (B) Tumor cells cultured in estrogen-
supplemented media. (C) Tumor cells cultured in estrogen-depleted media. (D) Integrin β1 (ITGB1) knockdown tumor cells and untreated cells cultured in 
estrogen-depleted media. Integrin β1 knockdown was performed using short-hairpin RNAs (shRNAs), as described in Supplementary Fig. 6 and previously 
(Choi et al. 2012). Data presented are mean values of light absorbance rate at 450 nm, representing proliferative activity of each well; error bar: ±s.d. 
*P < 0.05. A full colour version of this figure is available at http://dx.doi.org/10.1530/ERC-16-0086.
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patient survival data (Szasz et  al. 2016). Patients were 
first categorized into those who underwent adjuvant 
endocrine therapy (including estrogen receptor blocker 
tamoxifen and aromatase inhibitor, n = 561) or those who 
did not undergo endocrine therapy (n = 435). Then, the 
patients were further stratified into two groups based on 
angiopoietin-2 mRNA (ANGPT2) levels in tumor tissue. 
For those who underwent antiestrogen endocrine therapy, 
increased ANGPT2 level was associated with a significantly 
decreased probability of distant metastasis-free survival 
(DMFS) (Fig.  7A). For those without endocrine therapy, 
contrastingly, ANGPT2 level was not associated with 
the probability of DMFS (Fig.  7B). We did not perform 
a multivariate analysis incorporating known prognostic 
indicators such as tumor size, grade and number of 
axillary lymph nodes involved.
Discussion
The objective of this study was to investigate the effects 
of estrogen deficiency on BM microenvironment and 
dormancy of residing ER+ breast tumor cells. We found 
that prolonged estrogen depletion turned the BM niche 
in to pro-tumorigenic state, mainly by upregulating 
angiopoietin-2. Angiopoietin-2 ameliorated the dormancy 
of ER+ tumor cells in BM endothelial niche and promoted 
their survival under estrogen deficiency via integrin β1 
(ITGB1).
Physiologically, angiopoietin-2 destabilizes 
microvasculature and promotes angiogenesis, via 
interfering cell surface Tie2 receptor binding to 
angiopoeitin-1 or activating integrin β1 (Augustin 
et  al. 2009, Hakanpaa et  al. 2015). Its overexpression 
has been noted in many types of tumors and linked to 
poor prognosis (Eroglu et  al. 2013). In ovarian cancer, 
angiopoietin promotes intraperitoneal tumor growth 
by accumulating cancer-promoting fibroblasts and 
enhancing tumor angiogenesis (Brunckhorst et al. 2014). 
In pancreatic cancer, angiopoietin-2 drives lymphatic 
metastasis (Schulz et  al. 2011). In breast cancer, it 
impairs the blood–brain barrier and support tumor cell 
colonization in brain (Avraham et al. 2014). In our study, 
angiopoeitin-2 blocked endothelial Tie2 receptor activity, 
promoting ER+ tumor cell growth in otherwise growth-
suppressing endothelial niche. Thromospondin-1 (TSP-1) 
is the endothelium-derived growth inhibitory molecule 
acting on dormant breast tumor cells (Ghajar et al. 2013). 
Its level in endothelial niche correlated with the Tie2 
receptor activity, suggesting it is working in our model 
too. However, this is in contrast to a previous report that 
inhibition of Tie2 signaling induces endothelial TSP-1 
overexpression (Niu et  al. 2004). Our interpretation is 
that during angiogenesis, endothelial Tie2 activation 
promotes angiogenesis, lowering TSP-1 production; after 
vessels formed, endothelial Tie2 activation promotes 
vessel maturation (Hawighorst et  al. 2002), in which 
TSP-1 production is increased.
Our results underscore the direct action of 
angiopoietin-2 on ER+ tumor cells too. Unlike Tie2 
receptor, which is expressed exclusively in ECs, ITGB1 
is expressed in most epithelial tumor cells (Guo & 
Giancotti 2004). We showed that angiopoeitin-2 supported 
Figure 7
Distant metastasis-free survival of ER+ breast cancer patients, stratified 
by ANGPT2 expression. Kaplan–Meier analysis comparing distant 
metastasis-free survival of ER+ breast cancer patients following endocrine 
therapy (n = 561, A) and those without endocrine therapy (n = 435, B), 
distinguished by low versus high expressions of ANGPT2. Gene expression 
data obtained from the open-source KM Plotter (Szasz et al. 2016). 
Beeswarm graph plots of each RNA prove distribution. ANGPT2, 
angiopoietin-2 mRNA; ER, estrogen receptor.
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estrogen-independent tumor cell growth via ITGB1. 
Interestingly, it has been known that the activation of ITGB1 
turns dormant tumor cells into awakening state (White et al. 
2004). In addition, angiopoietin-2 can stimulate tumor cell 
metastasis to lymph nodes and lung, via activating tumor 
cell ITGB1 (Imanishi et  al. 2007). When those findings 
combined, it is likely that inactivation of angiopoietin-2 
signaling would effectively prevent the metastatic 
recurrence of breast cancer, particularly of ER+ subtype.
Our study indicates that estrogen regulates 
angiopoietin-2 expression in BM microenvironment. 
There appears to be a complex relationship between 
estrogen level and angiopoietin-1, 2 expressions. Glinskii 
and coworkers (2007) reported that cessation of ovarian 
hormone significantly reduced angiopoietin-1 expression 
in meningeal microvasculature. Similarly, Ardelt and 
coworkers (2005) reported that estradiol (E2) increased 
angiopoietin-1 expression in cerebral vascular beds, and 
Bonagura and coworkers (2010) reported that E2 increased 
angiopoietin-1 expression in endometrial glandular 
epithelial cells. In contrast, other reports showed that 
estrogen administration reduced angiopoietin-1 levels in 
placenta (Albrecht et al. 2008), in ER+ breast tumor cells 
(Harfouche et  al. 2011) and in some nonreproductive 
organs (Ye et  al. 2002). Furthermore, E2 treatment 
transiently increased angiopoietin-2 expression in ER+ 
T47D and ZR75.1 cells, while estrogen depletion also 
increased angiopoeitin-2 expression in these cells slowly 
but gradually (Sfiligoi et  al. 2003). These discrepancies 
may reflect differences in experimental conditions and 
tissue-specific regulatory mechanisms. Nevertheless, all 
studies suggest that sudden changes in estrogen levels 
do affect angiopoietin-2 expressions. Therefore, it will be 
valuable to compare systemic and local angiopoietin-2 
levels in pre- and postmenopausal women of breast 
cancer. Systemic angiopoietin-2 levels may be used as an 
alarm of disseminated tumor cell awakening too.
The in vitro culture system described here further limits 
the results of our study. Also, it should be borne in mind 
that in clinic, macroscopic metastases of ER+ breast cancer 
may present at a time that there is no apparent change 
in estrogen levels (Brackstone et al. 2007). Moreover, the 
experimental condition of rapid estrogen withdrawal 
is not necessarily same as the long-term low estrogen 
environment of adjuvant endocrine therapy setting. 
Therefore, these findings are purely experimental. However, 
we believe that the experimental design and results are 
consistent with existing in vivo models and results from 
human patient studies. We would like to state that any 
conditional overexpression of angiopoeitin-2, regardless 
of estrogen level, can provoke metastatic reactivation of 
solitarily disseminated tumor cells in estrogen-depleted 
bone microenvironment. Further, preclinical studies using 
angiopoietin-2 inhibitors in the premetastatic setting could 
add significance on our findings.
Treatment strategies for primary breast cancer have 
been successful. However, for metastatic disease, currently 
available therapeutic tools are still considered inadequate. 
ER+ breast cancer is of particular concern because its 
metastasis often precedes a period of dormancy. Dormant 
ER+ tumor cells in BM niche are thought to be the seed 
of metastasis. They are rare and difficult to identify and 
monitor using currently available methods, and are 
protected by the microenvironment and their own unique 
state from conventional cytotoxic chemotherapies. 
Conversely, dormant tumor cells are not harmful until 
they become activated and proliferate to form a tumor. 
Therefore, presence of dormant tumor cells also indicates 
an opportunity to control metastatic disease even before 
becoming apparent. Based on current findings, further 
studies are mandatory to verify the effect of angiopoietin-2 
signaling manipulation on late recurrence prevention in 
women with breast cancer, particularly those under risk of 
estrogen deficiency.
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